bluebird bio, Inc.
BLUE evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Lead Asset:
- LYFGENIA (Approved)
What it means
What to watch
Prepared research question
What matters most for BLUE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
LYFGENIA (Approved)
Next Catalyst
—
Tracking 3 pipeline candidates for bluebird bio, Inc..
Run bluebird bio, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available bluebird bio, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Governance
Frequently asked questions
What is bluebird bio, Inc.'s lead drug candidate?
bluebird bio, Inc.'s most advanced tracked candidate is LYFGENIA (Approved) for Treatment of patients 12 years of age or older with sickle cell disease and a history of vaso-occlusive events.
Who is the CEO of bluebird bio, Inc.?
Grand Un is the chief executive officer of bluebird bio, Inc. (BLUE).
What therapeutic areas does bluebird bio, Inc. focus on?
bluebird bio, Inc. develops therapies across Oncology, Rare Disease, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.